Verastem Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Verastem şirketinin toplam hissedar öz sermayesi $50.0M ve toplam borcu $81.7M olup, bu da borç-öz sermaye oranını 163.5% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $206.5M ve $156.5M dir.

Anahtar bilgiler

163.48%

Borç/özkaynak oranı

US$81.72m

Borç

Faiz karşılama oranı	n/a
Nakit	US$136.35m
Eşitlik	US$49.99m
Toplam yükümlülükler	US$156.53m
Toplam varlıklar	US$206.51m

Son finansal sağlık güncellemeleri

Recent updates

Anlatı Güncellemesi • Jun 26

VSTM: Future KRAS Data And Pancreatic Trial Progress Will Drive Repricing

The Verastem analyst price target has been revised lower, with a fair value estimate moving from about $14.00 to about $8.85 as analysts factor in a less favorable long thesis in a more crowded competitive space and updated post-earnings models. Analyst Commentary on Verastem Recent Street research on Verastem reflects a more cautious tone, with several bearish analysts trimming their fair value assumptions and reassessing the long thesis after recent earnings and competitive updates.

Analiz Makalesi • May 11

Analysts Are Updating Their Verastem, Inc. (NASDAQ:VSTM) Estimates After Its First-Quarter Results

It's been a sad week for Verastem, Inc. ( NASDAQ:VSTM ), who've watched their investment drop 18% to US$4.89 in the...

Yeni Anlatı • Jan 22

RAS And MAPK Cancer Pipeline Will Drive Long Term Upside Potential

Catalysts About Verastem Verastem is an oncology company focused on therapies for RAS and MAPK pathway driven cancers, including KRAS mutated recurrent low grade serous ovarian cancer. What are the underlying business or industry changes driving this perspective?

Analiz Makalesi • Dec 26

Verastem, Inc.'s (NASDAQ:VSTM) Share Price Is Still Matching Investor Opinion Despite 26% Slump

Verastem, Inc. ( NASDAQ:VSTM ) shareholders won't be pleased to see that the share price has had a very rough month...

Seeking Alpha • Jul 16

Verastem: The Market Is Ignoring The Progress

Summary FDA approval of AVMAPKI FAKZYNJA CO-PACK marks a transformative milestone, positioning Verastem as a commercial-stage leader in KRAS-mutant LGSOC treatment. Verastem's strong cash position and promising pipeline, including VS-7375 for KRAS G12D, offer significant upside with multiple near-term catalysts ahead. Risks include slow commercial uptake, pipeline uncertainty, and potential future dilution, but current valuation under $5 presents an attractive entry point. I maintain a 3/5 conviction, plan to add to my position below $5.75, and aim to hold long-term as VSTM targets KRAS-driven cancers. Read the full article on Seeking Alpha

Seeking Alpha • May 26

Verastem: Narrowed Market And Less Compelling Efficacy Warrant Rating Downgrade

Summary Verastem's stock plummeted after updates showed reduced efficacy in cancer treatment trials, causing a reassessment of strategy. Updated clinical trial results show a significant drop in response rates, suggesting less robust efficacy than earlier believed. Financially, Verastem has only a year of cash runway and faces significant dilution risks to extend it. Downgrade the recommendation to 'hold' due to increased risks and market volatility associated with microcap stocks. Read the full article on Seeking Alpha

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: VSTM 'nin kısa vadeli varlıkları ( $176.2M ) kısa vadeli yükümlülüklerini ( $78.1M ) aşıyor.

Uzun Vadeli Yükümlülükler: VSTM şirketinin kısa vadeli varlıkları ( $176.2M ) uzun vadeli yükümlülüklerini ( $78.4M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: VSTM şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: VSTM şirketinin borç/öz sermaye oranı son 5 yılda 23% seviyesinden 163.5% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: VSTM şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: VSTM serbest nakit akışı her yıl % 22.4 1 yıl yetecek nakit akışına sahip olacaktır.

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/08/08 08:51
Gün Sonu Hisse Fiyatı	2026/08/07 00:00
Kazançlar	2026/06/30
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Verastem, Inc. 28 Bu analistlerden 9, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
James Molloy	Alliance Global Partners
Matthew Cross	Alliance Global Partners
George Zavoico	B. Riley Securities, Inc.

Verastem Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Verastem, Inc. Auditor Raises 'Going Concern' Doubt

Verastem Oncology Announces 1-for-12 Reverse Stock Split to Satisfy the Price Requirement for Continued Listing on the Nasdaq Global Market

Recent updates

New minor risk - Financial position

Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer

Verastem, Inc. to Report Q2, 2026 Results on Aug 06, 2026

New minor risk - Share price stability

New minor risk - Insider selling

Verastem, Inc.(NasdaqCM:VSTM) dropped from Russell 3000 Value Benchmark

VSTM: Future KRAS Data And Pancreatic Trial Progress Will Drive Repricing

Verastem Oncology Demonstrates Clinical Activity of Vs-7375 in Target-D 101 Phase 1/2 Clinical Trial in Patients with Advanced Kras G12d-Mutated Solid Tumors

Verastem Inc Announces Positive Updated Safety and Efficacy Results from Ramp 205 Phase 1B 2A Trial of Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab Paclitaxel in First Line Mpdac

Insufficient new directors

Verastem, Inc. Announces Board Changes

Analysts Are Updating Their Verastem, Inc. (NASDAQ:VSTM) Estimates After Its First-Quarter Results

Verastem, Inc. to Report Q1, 2026 Results on May 07, 2026

Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI FAKZYNJA Combination Therapy

Verastem, Inc., Annual General Meeting, May 21, 2026

New minor risk - Profitability

Forecast to breakeven in 2028

Verastem, Inc. to Report Q4, 2025 Results on Mar 04, 2026

Forecast to breakeven in 2028

RAS And MAPK Cancer Pipeline Will Drive Long Term Upside Potential

President recently sold US$74k worth of stock

Insufficient new directors

Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Verastem, Inc.'s (NASDAQ:VSTM) Share Price Is Still Matching Investor Opinion Despite 26% Slump

Verastem Oncology Announces Management Changes

President notifies of intention to sell stock

Verastem, Inc. has completed a Follow-on Equity Offering in the amount of $89.99962 million.

Consensus EPS estimates fall by 13%

Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2A Dose Escalation Trial of Vs-7375, an Oral Kras G12d (On/Off) Inhibitor, in Patients with Kras G12d Mutant Solid Tumors

Verastem, Inc. to Report Q3, 2025 Results on Nov 04, 2025

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma

Independent Director notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 20%

Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer

Verastem, Inc. to Report Q2, 2025 Results on Aug 07, 2025

Verastem Oncology Grants Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer

Consensus revenue estimates decrease by 11%

Verastem: The Market Is Ignoring The Progress

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology

Consensus revenue estimates fall by 28%

Verastem Oncology Announces Nature Medicine Publication of the Results from the First-In-Human Phase 1 FRAME Study of Avutometinib in Solid Tumors, Including Low-Grade Serious Ovarian Cancer

President recently sold US$91k worth of stock

New minor risk - Profitability

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/Off) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375) Inhibitor

Price target increased by 18% to US$15.75

Verastem Oncology Announces Positive Updated Results from Ramp 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-Of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma

Verastem, Inc. Announces that FDA Approves AVMAPKI FAKZYNJA for Treating KRAS-mutated Ovarian Cancer

Verastem, Inc. announced that it expects to receive $75.004271 million in funding

Verastem, Inc., Annual General Meeting, May 22, 2025

Verastem, Inc. Auditor Raises 'Going Concern' Doubt

Verastem Oncology Appoints Matthew E. Ros as Chief Operating Officer

Verastem, Inc. announced that it has received $75 million in funding

Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as A Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting

Verastem, Inc. has completed a Follow-on Equity Offering in the amount of $54.995002 million.

Verastem, Inc. has filed a Follow-on Equity Offering.

Verastem Oncology Announces First Patient Dosed with Gfh375/Vs-7375 in A Phase 1/2 Trial in China as Part of Collaboration with Genfleet Therapeutics

Verastem: Narrowed Market And Less Compelling Efficacy Warrant Rating Downgrade

Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer

Verastem Oncology Announces Executive Changes

Verastem, Inc., Annual General Meeting, May 23, 2024

Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Broader Pipeline in RAS Pathway-Driven Cancers

Verastem Oncology Announces Initiation of A Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Verastem Oncology Announces the Launch of the New Healthcare Professional Component

Verastem, Inc. has filed a Follow-on Equity Offering in the amount of $6.510455 million.

Verastem Oncology Announces Executive Appointments

Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ in KRAS G12C-Mutant Non-Small Cell Lung Cancer

Verastem, Inc. Appoints Daniel Paterson as Class III Director

Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer, Effective August 1, 2023